Recursion Pharmaceuticals Inc Inc. (RXRX) Price Performance: The Role of Supply and Demand

Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -14.79% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -6.34%. Over the past 30 days, the price of RXRX has leaped by -3.03%. And in the last five days, it has surged by 35.85%.

Recursion Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $12.36 on 02/18/25 and the lowest value was $3.79 on 04/09/25.

52-week price history of RXRX Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Recursion Pharmaceuticals Inc’s current trading price is -53.40% away from its 52-week high, while its distance from the 52-week low is 51.98%. The stock’s price range during this period has varied between$3.79 and $12.36. The Recursion Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 82.88 million for the day, a figure considerably higher than their average daily volume of 24.09 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly decline of -16.28% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.32B.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 6.91, with a change in price of -1.15. Similarly, Recursion Pharmaceuticals Inc recorded 21,584,004 in trading volume during the last 100 days, posting a change of -16.64%.

RXRX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.

RXRX Stock Stochastic Average

As of today, Recursion Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 22.99%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 62.54%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 37.57% and 23.75%, respectively.

Most Popular

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.